<DOC>
	<DOCNO>NCT00856297</DOCNO>
	<brief_summary>The primary objective evaluate persistence bactericidal antibodies adolescents previously enrol V59P13 study receive either Novartis MenACWY Conjugate Vaccine commercially available MenACWY conjugate vaccine . The study also enroll age-matched subject never receive meningococcal vaccine ( naïve subject ) serve additional control group .</brief_summary>
	<brief_title>Evaluation Persistence Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Subjects enrol V59P13 : healthy subject complete V59P13 study . Naïve subject : healthy subject agedmatched subject complete V59P13 trial . ( currently 1623 year old ) . Subjects complete V59P13 study : receive meningococcal vaccine V59P13 trial ; previous confirm suspected disease cause N. meningitidis ; household contact and/or intimate exposure individual cultureproven N. meningitidis ( serogroups A , C , W135 , Y ) ; subject serious , acute chronic progressive disease . Naïve subject : previously receive meningococcal vaccine ; previous confirm suspected disease cause N. meningitidis ; household contact and/or intimate exposure individual cultureproven N. meningitidis ( serogroups A , C , W135 , Y ) ; subject serious , acute chronic progressive disease .</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Meningococcal</keyword>
	<keyword>ACWY</keyword>
	<keyword>Conjugate Vaccine</keyword>
	<keyword>Meningitis</keyword>
	<keyword>Adolescents</keyword>
	<keyword>Persistence</keyword>
</DOC>